- Acquiring assets and licensing worldwide rights to manufacture and supply customers
- Imagion focuses all resources on advancing its clinical pipeline
THEBARTON, Australia, October 10th, 2024 - Biosensis, the leading provider of Neurobiology biomarker tools and assays for Life Science applications, today announced they entered into an asset transfer and IP license agreement with Imagion Biosystems under which Biosensis will offer Imagion’s PrecisionMRX® Superparamagnetic Iron Oxide Nanoparticle (SPION) products and CRO services to academic and biotech customers. Under the agreement terms, Biosensis will pay Imagion royalites and milestone payments. Biosensis will have rights to further develop and commercialize the PrecisionMRX® technology for biomedical research applications.
High quality, SPIONs with precise dimensions are critical. PrecisionMRX® manufacturing technology is tunable and allows for exquisite control of size and uniform dimensions. The PrecisionMRX® manufacturing technology includes conjugation of antibodies and other biomolecules to the SPIONs allowing for a broad set of applications including vaccines, molecular imaging and hyperthermal tumor ablation.
“This agreement signals a transformation of Biosensis to expand our portfolio with novel biosensor technologies,” said Robert Rush, Chairman of the Board, Biosensis. “Our customers will benefit as we continue to develop the product offering of high precision SPIONs.”
“We are very pleased to be entering into this strategic agreement with Biosensis, since it puts our products and technology into the hands of a very capable team able to serve a customer base we have developed but that is not in Imagion’s future scope,” said Robert Proulx, Chairman of Imagion Biosystems. “We can now focus all our resources on advancing our clinical pipeline while still benefiting from our technology being commercialized in other applications.”
About Biosensis Pty Ltd.
Biosensis is a leading life science company focused on advancing research, particularly in the field of neuroscience, Biosensis, specializes in development, manufacturing and commercialization of high-quality biological reagents, assays, and diagnostic tools supporting breakthroughs in understanding neurodegenerative diseases, neurobiology, and brain health. With a strong commitment to quality and innovation, Biosensis products empower researchers to drive discoveries in neuroscience and drug development. Its fully-owned subsidiary Gropep BioReagents, provides ISO:9001 proteins to researchers and diagnostic companies.
About Imagion Biosystems, Inc.
Imagion Biosystems is developing a new non-radioactive and precision diagnostic molecular imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible.
Learn More About PrecisionMRX® Superparamagnetic Iron Oxide Nanoparticle (SPION) Products